Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2024 Sep 16

PMID 39285122

Authors

Kennedy Sparling

Daniel C Butler

Affiliations

Soon will be listed here.

Abstract

Corticosteroids play a crucial role as anti-inflammatory and immunomodulatory agents in dermatology and other medical specialties; however, their therapeutic benefits are accompanied by significant risks, especially in older adults. This review examines the broad spectrum of adverse effects (AEs) associated with oral corticosteroid therapy and offers strategies to prevent, monitor, and manage these issues effectively in older adults. AEs associated with systemic corticosteroids include immune suppression, gastrointestinal problems, hyperglycemia, insulin resistance, weight gain, cardiovascular complications, ocular issues, osteoporosis, osteonecrosis, muscle weakness, collagen impairment, psychiatric symptoms, and adrenal suppression. To minimize these AEs, tailored dosing and duration, frequent monitoring, and additional preventative measures can be employed to optimize corticosteroid treatment. By customizing management plans to the specific needs and risk factors associated with each patient, clinicians can promote the safe and effective use of oral corticosteroids, ultimately improving outcomes and quality of life in patients with inflammatory dermatologic disorders.

References

Auphan N, DiDonato J, Rosette C, Helmberg A, Karin M . Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995; 270(5234):286-90. DOI: 10.1126/science.270.5234.286. View

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn E, Leigh R . A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013; 9(1):30. PMC: 3765115. DOI: 10.1186/1710-1492-9-30. View

Drucker A, Eyerich K, de Bruin-Weller M, Thyssen J, Spuls P, Irvine A . Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2017; 178(3):768-775. PMC: 5901393. DOI: 10.1111/bjd.15928. View

Buonavoglia A, Leone P, Dammacco R, Di Lernia G, Petruzzi M, Bonamonte D . Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Autoimmun Rev. 2019; 18(4):349-358. DOI: 10.1016/j.autrev.2019.02.005. View

Overman R, Yeh J, Deal C . Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2012; 65(2):294-8. DOI: 10.1002/acr.21796. View

Marcus M, Muskens R, Ramdas W, Wolfs R, de Jong P, Vingerling J . Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study. Drugs Aging. 2012; 29(12):963-70. DOI: 10.1007/s40266-012-0029-9. View

Curtis J, Westfall A, Allison J, Bijlsma J, Freeman A, George V . Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006; 55(3):420-6. DOI: 10.1002/art.21984. View

Borradori L, van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R . Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022; 36(10):1689-1704. DOI: 10.1111/jdv.18220. View

Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z . Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007; 57(4):622-8. DOI: 10.1016/j.jaad.2007.05.024. View

10.

Schmidt E, Sticherling M, Sardy M, Eming R, Goebeler M, Hertl M . . J Dtsch Dermatol Ges. 2020; 18(5):516-527. DOI: 10.1111/ddg.14097_g. View

11.

Yu S, Drucker A, Lebwohl M, Silverberg J . A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2017; 78(4):733-740.e11. DOI: 10.1016/j.jaad.2017.09.074. View

12.

Ramamoorthy S, Cidlowski J . Corticosteroids: Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2015; 42(1):15-31, vii. PMC: 4662771. DOI: 10.1016/j.rdc.2015.08.002. View

13.

Czock D, Keller F, Rasche F, Haussler U . Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; 44(1):61-98. DOI: 10.2165/00003088-200544010-00003. View

14.

Gom I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K . Relationship between serum albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci Vitaminol (Tokyo). 2007; 53(1):37-42. DOI: 10.3177/jnsv.53.37. View

15.

Piper J, Ray W, Daugherty J, Griffin M . Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991; 114(9):735-40. DOI: 10.7326/0003-4819-114-9-735. View

16.

Tseng C, Chen Y, Huang C, Luo J, Peng Y, Huang D . Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther. 2015; 42(5):599-606. DOI: 10.1111/apt.13298. View

17.

Tornatore K, Logue G, Venuto R, Davis P . Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc. 1994; 42(10):1118-22. DOI: 10.1111/j.1532-5415.1994.tb06219.x. View

18.

Bajaj J, Wong F, Kamath P, Lai J, OLeary J . Acute-on-Chronic Liver Failure. Am J Gastroenterol. 2022; 117(6):831-834. DOI: 10.14309/ajg.0000000000001748. View

20.

Da Silva J, Jacobs J, Kirwan J, Boers M, Saag K, Ines L . Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2005; 65(3):285-93. PMC: 1798053. DOI: 10.1136/ard.2005.038638. View

21.

Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R . Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2008; 68(7):1119-24. DOI: 10.1136/ard.2008.092163. View